Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1284)	12/2/2002 9:05:39 AM
From: nigel bates	Respond to of 1784

CombiMatrix Completes $5.5 Million in Milestones in Strategic Alliance with Roche NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Dec. 2, 2002--Acacia Research Corporation (Nasdaq:ACRI - News) announced today that its subsidiary, CombiMatrix, has completed a number of additional R&D milestones in its strategic alliance with Roche Applied Science. Completion of these milestones will result in additional payments to CombiMatrix of $5.5 million during the fourth quarter. There remain additional milestones to be achieved before product launch. CombiMatrix' strategic alliance with Roche includes a collaboration for the development and commercialization of CombiMatrix' DNA microarray technology, enabling flexible and fast custom manufacturing of microarrays by electrochemical oligonucleotide synthesis in-situ. Under the terms of the agreement, Roche will market the hybridization-reader instrument, flexible custom content microarrays, and pre-designed "catalogue" content microarrays in combination with its own matching labeling and hybridization reagents as well as bioinformatic tools. About CombiMatrix CombiMatrix is developing a platform technology that has a wide range of applications, from DNA synthesis/diagnostics to immunochemical detection. The platform allows the company to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The company is designing its products principally to be responsive to the needs of pharmaceutical, biotechnology, and academic researchers in analyzing raw genomic data in the discovery and development of pharmaceutical products. CombiMatrix's Web site is located at www.combimatrix.com.